|
SG176313A1
(en)
*
|
2001-10-01 |
2011-12-29 |
Univ Virginia Patent Found |
2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
|
|
GT200500281A
(es)
*
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
EP1831225A2
(en)
|
2004-11-19 |
2007-09-12 |
The Regents of the University of California |
Anti-inflammatory pyrazolopyrimidines
|
|
GB0500785D0
(en)
*
|
2005-01-14 |
2005-02-23 |
Novartis Ag |
Organic compounds
|
|
US8178509B2
(en)
*
|
2006-02-10 |
2012-05-15 |
University Of Virginia Patent Foundation |
Method to treat sickle cell disease
|
|
EA200870409A1
(ru)
|
2006-04-04 |
2009-04-28 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Антагонисты киназы pi3
|
|
ATE549337T1
(de)
|
2006-04-21 |
2012-03-15 |
Novartis Ag |
Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
|
|
GB0607950D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
US8188063B2
(en)
*
|
2006-06-19 |
2012-05-29 |
University Of Virginia Patent Foundation |
Use of adenosine A2A modulators to treat spinal cord injury
|
|
ES2361886T3
(es)
*
|
2006-06-27 |
2011-06-24 |
Cbt Development Limited |
Profármacos adenosina acetil 2',3'-metilideno novedosos para uso como profármacos para agonistas del receptor adenosina.
|
|
EP1889846A1
(en)
*
|
2006-07-13 |
2008-02-20 |
Novartis AG |
Purine derivatives as A2a agonists
|
|
US7985754B2
(en)
*
|
2006-07-17 |
2011-07-26 |
Trovis Pharmaceuticals, Llc |
Selective antagonists of A2A adenosine receptors
|
|
EP1903044A1
(en)
*
|
2006-09-14 |
2008-03-26 |
Novartis AG |
Adenosine Derivatives as A2A Receptor Agonists
|
|
JP2010508835A
(ja)
*
|
2006-11-10 |
2010-03-25 |
ノバルティス アーゲー |
シクロペンテンジオールモノアセテート誘導体
|
|
GB2467670B
(en)
|
2007-10-04 |
2012-08-01 |
Intellikine Inc |
Chemical entities and therapeutic uses thereof
|
|
US8058259B2
(en)
|
2007-12-20 |
2011-11-15 |
University Of Virginia Patent Foundation |
Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
CA2711558C
(en)
|
2008-01-04 |
2016-12-13 |
Intellikine, Inc. |
Phosphatidyl inositol-3 kinase inhibiting compounds
|
|
US8993580B2
(en)
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン， エルエルシー |
キナーゼ阻害剤および使用方法
|
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
|
AU2009268611B2
(en)
|
2008-07-08 |
2015-04-09 |
Intellikine, Llc |
Kinase inhibitors and methods of use
|
|
JP5731978B2
(ja)
|
2008-09-26 |
2015-06-10 |
インテリカイン， エルエルシー |
複素環キナーゼ阻害剤
|
|
CA2740885C
(en)
|
2008-10-16 |
2018-04-03 |
The Regents Of The University Of California |
Fused ring heteroaryl kinase inhibitors
|
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
|
EP2427195B1
(en)
|
2009-05-07 |
2019-05-01 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
|
WO2011143442A1
(en)
*
|
2010-05-12 |
2011-11-17 |
Trovis Pharmaceuticals, Llc. |
A method of treating multiple sclerosis with adenosine receptor agonists
|
|
AU2011255218B2
(en)
|
2010-05-21 |
2015-03-12 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
|
EP2608794A4
(en)
*
|
2010-08-26 |
2014-01-22 |
Univ Northeastern |
METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING OIL CONTAINER
|
|
JP5921555B2
(ja)
|
2010-09-29 |
2016-05-24 |
エスケー バイオファーマシューティカルズ カンパニー リミテッド |
新規メチルシクロヘキサン誘導体およびその使用
|
|
JP2013545749A
(ja)
|
2010-11-10 |
2013-12-26 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
複素環化合物及びその使用
|
|
JP5931905B2
(ja)
|
2010-12-03 |
2016-06-08 |
エピザイム，インコーポレイティド |
置換プリン及び７‐デアザプリン化合物
|
|
AU2011336272A1
(en)
|
2010-12-03 |
2013-06-20 |
Epizyme, Inc. |
7-deazapurine modulators of histone methyltransferase, and methods of use thereof
|
|
AU2012205669B2
(en)
|
2011-01-10 |
2015-08-20 |
Infinity Pharmaceuticals Inc. |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
|
JP6130305B2
(ja)
|
2011-02-23 |
2017-05-17 |
インテリカイン， エルエルシー |
キナーゼ阻害剤の組み合わせおよびそれらの使用
|
|
US9132131B2
(en)
|
2011-04-21 |
2015-09-15 |
Saint Louis University |
Use of adenosine A3 receptor agonists for treatment of neuropathic pain
|
|
US9056877B2
(en)
|
2011-07-19 |
2015-06-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
JP6027610B2
(ja)
|
2011-07-19 |
2016-11-16 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
複素環式化合物及びその使用
|
|
EP2751093A1
(en)
|
2011-08-29 |
2014-07-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
|
CN104363757B
(zh)
*
|
2012-02-11 |
2017-05-24 |
中央研究院 |
治疗疼痛的方法及组合物
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
WO2014026198A1
(en)
|
2012-08-10 |
2014-02-13 |
Epizyme, Inc. |
Inhibitors of protein methyltransferase dot1l and methods of use thereof
|
|
CA2883781A1
(en)
|
2012-09-06 |
2014-03-13 |
Epizyme, Inc. |
Method of treating leukemia
|
|
MX2015003874A
(es)
|
2012-09-26 |
2015-12-16 |
Univ California |
Modulacion de ire1.
|
|
KR102229478B1
(ko)
|
2012-11-01 |
2021-03-18 |
인피니티 파마슈티칼스, 인코포레이티드 |
Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
|
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
EP2968387A4
(en)
|
2013-03-15 |
2017-04-05 |
Epizyme, Inc. |
Methods of synthesizing substituted purine compounds
|
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
PE20160685A1
(es)
|
2013-10-04 |
2016-07-23 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos
|
|
SG10201808053XA
(en)
|
2014-03-19 |
2018-10-30 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
|
US10160761B2
(en)
|
2015-09-14 |
2018-12-25 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
|
|
WO2017160930A1
(en)
*
|
2016-03-16 |
2017-09-21 |
Kalyra Pharmaceuticals, Inc. |
Analgesic compounds
|
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
MX391135B
(es)
|
2016-06-24 |
2025-03-21 |
Infinity Pharmaceuticals Inc |
Terapias de combinacion.
|
|
WO2018035380A1
(en)
|
2016-08-17 |
2018-02-22 |
Solstice Biologics, Ltd. |
Polynucleotide constructs
|
|
WO2019006455A1
(en)
|
2017-06-30 |
2019-01-03 |
Solstice Biologics, Ltd. |
AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
|